Abstract

We carried out a study to compare the performance, in terms of sensitivity and specificity, of the new SD BIOLINE® HAT rapid diagnostic test (RDT) with the card agglutination test for trypanosomiasis (CATT) for diagnosis of human African trypanosomiasis (HAT) in the Democratic Republic of the Congo (DRC). Participants were enrolled actively by four mobile teams, and passively at four health facilities in three provinces. Consenting participants were tested concurrently with the RDT and CATT on whole blood. Those found positive by either test were tested with CATT on serial dilutions of plasma, and with a parasitological composite reference standard (CRS). Cases were only the individuals found positive by the CRS, while controls were negative by both CATT and RDT, as well as those that were positive by CATT or RDT, but were negative by the CRS, and had no history of HAT. Over five months, 131 cases and 13,527 controls were enrolled. The sensitivity of the RDT was 92.0% (95% confidence interval (CI) = 86.1–95.5), which was significantly higher than CATT (sensitivity 69.1%; 95% CI = 60.7–76.4). The sensitivity of CATT on plasma at a dilution of 1:8 was 59.0% (95% CI = 50.2–67.2). The specificity of the RDT was 97.1% (95% CIs = 96.8–97.4) while that of CATT was 98.0% (95% CIs = 97.8, 98.2) and specificities of algorithms involving CATT at 1:8 dilution were 99.6% (95% CI = 99.5–99.7). Reproducibility of results was excellent. We concluded that an algorithm in which the SD BIOLINE® HAT RDT is used for screening is optimal for case detection in both passive and active screening settings. However, the lower specificity of the RDT compared to that of CATT would result in a larger number of false positive individuals undergoing confirmatory testing.

Highlights

  • Human African trypanosomiasis (HAT), known as sleeping sickness, is a vector-borne parasitic disease transmitted to humans by the bite of an infected tsetse fly (Glossina spp)

  • Ð1 À sensitivityÞ x prevalence þ specificity x ð1 À prevalenceÞ. To make this a statistic that can be translated by a surveillance programme, we present the false discovery rate (FDR) and false omission rate (FOR) as: FDR 1⁄4 1 À positive predictive value (PPV)

  • Cases were diagnosed by gland puncture, mHCT and mini-anion exchange centrifugation technique (mAECT) in almost equal proportions, while 4 cases were only positive by cerebrospinal fluid (CSF) examination

Read more

Summary

Introduction

Human African trypanosomiasis (HAT), known as sleeping sickness, is a vector-borne parasitic disease transmitted to humans by the bite of an infected tsetse fly (Glossina spp). The disease is endemic in sub-Saharan Africa, within the limits of the geographic distribution of the tsetse fly. Two sub-species of the protozoan parasite Trypanosoma brucei cause the disease in humans: T.b. gambiense and T.b. rhodesiense. Gambiense HAT is endemic in rural, resource-limited settings, mainly in west and central Africa, with the majority of cases reported in the Democratic Republic of the Congo (DRC) [2]. The number of cases of HAT reported globally has been falling steadily, and the disease is targeted for elimination as a public health problem by 2020 [3]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call